Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Salvatore Spazzapan
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer
Journal of Cancer
Oncology
Efficacy of Irinotecan as Third-Line Chemotherapy for Unresectable or Recurrent Gastric Cancer
In Vivo
Biochemistry
Medicine
Genetics
Pharmacology
Molecular Biology
Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients
OncoTargets and Therapy
Oncology
Pharmacology
Eribulin Mesylate in the Treatment of Metastatic Breast Cancer
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
First-Line Single-Agent Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer With Poor Performance Status
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Helical TomoTherapy for Locally Advanced or Recurrent Breast Cancer
Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
Analysis of Eribulin Mesylate Dosing Modifications Impact on Administration Persistence in Patients With Metastatic Breast Cancer (Mbc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Weekly Paclitaxel as Second-Line Chemotherapy for Advanced or Recurrent Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
